News Conference News AHA 2024 SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity Michael O'Riordan November 16, 2024
News Conference News AHA 2022 Four Drugs, One Pill: QUARTET USA Supports New Strategy for BP-Lowering Caitlin E. Cox November 08, 2022
News Conference News AHA 2022 In High BP, Chlorthalidone and Hydrochlorothiazide Have Similar Impact on MACE Todd Neale November 05, 2022
News Conference News AHA 2020 Rilonacept Prevents Recurrent Pericarditis: RHAPSODY Shelley Wood November 17, 2020
News Conference News AHA 2019 Early Data Favorable for New RNAi Therapies to Reduce Triglycerides Caitlin E. Cox November 19, 2019
News Conference News AHA 2018 Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study Michael O'Riordan November 15, 2018
News Conference News AHA 2018 Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI Michael O'Riordan November 14, 2018
News Conference News AHA 2016 Dabigatran Reversal Agent’s Safety, Efficacy Affirmed With Updated Study Results Todd Neale November 15, 2016
News Conference News AHA 2016 Cardiac Arrest Survival Higher in Patients Already Taking Statins Todd Neale November 12, 2016